Literature DB >> 27687135

A Self-restricted CRISPR System to Reduce Off-target Effects.

Yanhao Chen1, Xiaojian Liu1, Yongxian Zhang1, Hui Wang2, Hao Ying2, Mingyao Liu3, Dali Li3, Kathy O Lui4, Qiurong Ding1.   

Abstract

Mesh：

Year:  2016        PMID： 27687135      PMCID： PMC5113117          DOI： 10.1038/mt.2016.172

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  11 in total

1.  Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity.

Authors:  F Ann Ran; Patrick D Hsu; Chie-Yu Lin; Jonathan S Gootenberg; Silvana Konermann; Alexandro E Trevino; David A Scott; Azusa Inoue; Shogo Matoba; Yi Zhang; Feng Zhang
Journal:  Cell       Date:  2013-08-29       Impact factor: 41.582

Review 2.  Development and applications of CRISPR-Cas9 for genome engineering.

Authors:  Patrick D Hsu; Eric S Lander; Feng Zhang
Journal:  Cell       Date:  2014-06-05       Impact factor: 41.582

3.  Improved vectors and genome-wide libraries for CRISPR screening.

Authors:  Neville E Sanjana; Ophir Shalem; Feng Zhang
Journal:  Nat Methods       Date:  2014-08       Impact factor: 28.547

4.  Small molecule-triggered Cas9 protein with improved genome-editing specificity.

Authors:  Kevin M Davis; Vikram Pattanayak; David B Thompson; John A Zuris; David R Liu
Journal:  Nat Chem Biol       Date:  2015-04-06       Impact factor: 15.040

5.  Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins.

Authors:  Sojung Kim; Daesik Kim; Seung Woo Cho; Jungeun Kim; Jin-Soo Kim
Journal:  Genome Res       Date:  2014-04-02       Impact factor: 9.043

Review 6.  Genome-editing Technologies for Gene and Cell Therapy.

Authors:  Morgan L Maeder; Charles A Gersbach
Journal:  Mol Ther       Date:  2016-01-12       Impact factor: 11.454

7.  Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing.

Authors:  Shengdar Q Tsai; Nicolas Wyvekens; Cyd Khayter; Jennifer A Foden; Vishal Thapar; Deepak Reyon; Mathew J Goodwin; Martin J Aryee; J Keith Joung
Journal:  Nat Biotechnol       Date:  2014-04-25       Impact factor: 54.908

8.  High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects.

Authors:  Benjamin P Kleinstiver; Vikram Pattanayak; Michelle S Prew; Shengdar Q Tsai; Nhu T Nguyen; Zongli Zheng; J Keith Joung
Journal:  Nature       Date:  2016-01-06       Impact factor: 49.962

9.  An easy and efficient inducible CRISPR/Cas9 platform with improved specificity for multiple gene targeting.

Authors:  Jian Cao; Lizhen Wu; Shang-Min Zhang; Min Lu; William K C Cheung; Wesley Cai; Molly Gale; Qi Xu; Qin Yan
Journal:  Nucleic Acids Res       Date:  2016-07-25       Impact factor: 16.971

10.  Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo.

Authors:  Hao Yin; Chun-Qing Song; Joseph R Dorkin; Lihua J Zhu; Yingxiang Li; Qiongqiong Wu; Angela Park; Junghoon Yang; Sneha Suresh; Aizhan Bizhanova; Ankit Gupta; Mehmet F Bolukbasi; Stephen Walsh; Roman L Bogorad; Guangping Gao; Zhiping Weng; Yizhou Dong; Victor Koteliansky; Scot A Wolfe; Robert Langer; Wen Xue; Daniel G Anderson
Journal:  Nat Biotechnol       Date:  2016-02-01       Impact factor: 54.908
View more
  27 in total

1.  CRISPR-Induced Deletion with SaCas9 Restores Dystrophin Expression in Dystrophic Models In Vitro and In Vivo.

Authors:  Benjamin L Duchêne; Khadija Cherif; Jean-Paul Iyombe-Engembe; Antoine Guyon; Joel Rousseau; Dominique L Ouellet; Xavier Barbeau; Patrick Lague; Jacques P Tremblay
Journal:  Mol Ther       Date:  2018-08-16       Impact factor: 11.454

2.  The technical risks of human gene editing.

Authors:  Benjamin Davies
Journal:  Hum Reprod       Date:  2019-11-01       Impact factor: 6.918

Review 3.  Adenoviral vectors for in vivo delivery of CRISPR-Cas gene editors.

Authors:  Paul Boucher; Xiaoxia Cui; David T Curiel
Journal:  J Control Release       Date:  2020-09-03       Impact factor: 9.776

4.  Doxycycline-Dependent Self-Inactivation of CRISPR-Cas9 to Temporally Regulate On- and Off-Target Editing.

Authors:  Anju Kelkar; Yuqi Zhu; Theodore Groth; Gino Stolfa; Aimee B Stablewski; Naina Singhi; Michael Nemeth; Sriram Neelamegham
Journal:  Mol Ther       Date:  2019-09-12       Impact factor: 11.454

Review 5.  CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia.

Authors:  Alexandra C Chadwick; Kiran Musunuru
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-08-24       Impact factor: 8.311

6.  Naïve Primary Mouse CD8+ T Cells Retain In Vivo Immune Responsiveness After Electroporation-Based CRISPR/Cas9 Genetic Engineering.

Authors:  Petra Pfenninger; Laura Yerly; Jun Abe
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

Review 7.  Genome Editing: The Recent History and Perspective in Cardiovascular Diseases.

Authors:  Kiran Musunuru
Journal:  J Am Coll Cardiol       Date:  2017-12-05       Impact factor: 24.094

Review 8.  Ex vivo cell-based CRISPR/Cas9 genome editing for therapeutic applications.

Authors:  Yamin Li; Zachary Glass; Mingqian Huang; Zheng-Yi Chen; Qiaobing Xu
Journal:  Biomaterials       Date:  2020-01-10       Impact factor: 12.479

Review 9.  Small nucleic acids and the path to the clinic for anti-CRISPR.

Authors:  Christopher L Barkau; Daniel O'Reilly; Seth B Eddington; Masad J Damha; Keith T Gagnon
Journal:  Biochem Pharmacol       Date:  2021-02-27       Impact factor: 6.100

Review 10.  Genome and base editing for genetic hearing loss.

Authors:  Philipp Niggemann; Bence György; Zheng-Yi Chen
Journal:  Hear Res       Date:  2020-04-05       Impact factor: 3.208
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.